Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus Expanded Access in Advanced NETs
NCT01595009Phase 4Completed
- Sponsor
- Novartis
- Start
- Apr 2011
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of everolimus in neuroendocrine tumors (NETs), sponsored by Novartis. Primary endpoint: Number and Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Deaths up to 4 years. Started Apr 2011; status: completed.
02
Drugs
everolimus
03
Conditions
neuroendocrine tumors (NETs)
Beyond the preview
Go deeper on NCT01595009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01595009.